😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

TREMFYA seeks FDA nod for Crohn's disease treatment

EditorNatashya Angelica
Published 21/06/2024, 07:18 am

SPRING HOUSE, Pa. - Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the approval of TREMFYA® (guselkumab) to treat adults with moderately to severely active Crohn's disease.

This submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programs, which indicate that TREMFYA® could become the first IL-23 inhibitor to offer both subcutaneous (SC) and intravenous (IV) induction therapy options for this condition.

The GALAXI program, which includes Phase 2 and 3 studies, evaluated the efficacy and safety of guselkumab in participants with Crohn's disease who had an inadequate response to conventional therapies or biologics. The results demonstrated that TREMFYA® met the co-primary endpoints for SC maintenance doses and showed superiority to ustekinumab in endoscopic endpoints.

Similarly, the GRAVITI study assessed TREMFYA® SC induction therapy, meeting its co-primary endpoints for clinical remission and endoscopic response at Week 12, with all multiplicity-controlled endpoints being met up to Week 48 compared to placebo.

David Lee, M.D., Ph.D., Global Therapeutic Area Head Immunology at Johnson & Johnson, emphasized the company's commitment to addressing the needs of people living with Crohn's disease and expressed hope for the FDA's review of the data.

TREMFYA®, a fully-human monoclonal antibody, blocks IL-23 and binds to CD64, potentially impacting the immune-mediated processes of Crohn's disease. It was first approved in July 2017 for the treatment of adult patients with moderate-to-severe plaque psoriasis and later for active psoriatic arthritis in July 2020.

The European Medicines Agency (EMA) has also received applications from Janssen-Cilag International NV, a Johnson & Johnson company, for the expansion of TREMFYA®'s indications to include ulcerative colitis and Crohn's disease.

This news is based on a press release statement from Johnson & Johnson. The company's ongoing commitment to immunology and innovation is evident in its pursuit of expanding TREMFYA®'s indications, potentially offering new treatment options for patients with inflammatory bowel diseases.

In other recent news, Johnson & Johnson (J&J) has been subject to a unique class action lawsuit seeking medical monitoring for women who may develop cancer from the use of the company's talc-based products.

Simultaneously, the company has submitted a Biologics License Application to the FDA for a new cancer treatment, amivantamab. On the financial front, RBC Capital has maintained an Outperform rating on J&J, following the presentation of encouraging data at a recent analyst meeting.

In the realm of treatment developments, J&J presented promising long-term data from its MonumenTAL-1 study, indicating durable responses in patients treated with its multiple myeloma treatment, TALVEY®. Meanwhile, law firms involved in opioid crisis settlements, which implicated J&J among other companies, were awarded a $2.13 billion legal fee pool.

These recent developments provide an overview of the various challenges and advancements J&J is currently navigating.

InvestingPro Insights

As Johnson & Johnson (NYSE: JNJ) seeks to expand the indications of TREMFYA® into the treatment of Crohn's disease, the company's financial health remains a key consideration for investors. With a robust market capitalization of $356.16 billion and a trailing twelve months revenue of $85.65 billion as of Q1 2023, JNJ's financial stability is evident.

The company's dedication to shareholder returns is highlighted by its impressive track record of increasing its dividend for 54 consecutive years, a testament to its financial strength and commitment to investors.

Investors may also find reassurance in JNJ's low price volatility, making it a potentially attractive option for those seeking stability in their portfolios. Additionally, JNJ's dividend yield stood at 3.41% as of mid-2024, further showcasing its role as a consistent income-generating stock.

For those looking to delve deeper into the company's financials and future prospects, InvestingPro provides valuable insights. Notably, JNJ is trading near its 52-week low, which may present a buying opportunity for long-term investors. Moreover, analysts predict the company will remain profitable this year, aligning with its profitable performance over the last twelve months.

For more detailed analysis and additional InvestingPro Tips, including JNJ's position as a prominent player in the Pharmaceuticals industry and its ability to sufficiently cover interest payments with cash flows, investors can visit https://www.investing.com/pro/JNJ. There are 9 additional InvestingPro Tips available, offering a comprehensive understanding of the company's financial metrics and industry standing.

Interested readers can take advantage of a special offer to access these insights: use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro. This exclusive discount provides an excellent opportunity to stay informed on JNJ's performance and potential as an investment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.